<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="correction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1514836</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Correction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Corrigendum: Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Siyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2801803"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Huang</surname>
<given-names>Changxin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yongqiang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhaoyang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Lili</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Haokun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sun</surname>
<given-names>Quan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Mengmeng</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cao</surname>
<given-names>Songqiang</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2758582"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Oncology, Affiliated Hospital of Hangzhou Normal University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Urology, Huaihe Hospital of Henan University</institution>, <addr-line>Kaifeng</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Wenxue Ma, University of California, San Diego, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Rong-Hua Tao, University of Texas MD Anderson Cancer Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Changxin Huang, <email xlink:href="mailto:hcx588@hotmail.com">hcx588@hotmail.com</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1514836</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>10</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>11</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Zhang, Huang, Li, Li, Zhu, Yang, Hu, Sun, Liu and Cao</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Zhang, Huang, Li, Li, Zhu, Yang, Hu, Sun, Liu and Cao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="corrected-article" journal-id="" journal-id-type="nlm-ta" xlink:href="10.3389/fimmu.2024.1473145" ext-link-type="doi">A Corrigendum on <article-title>Anti-cancer immune effect of human colorectal cancer neoantigen peptide based on MHC class I molecular affinity screening</article-title> By&#xa0;Zhang S, Huang C, Li Y, Li Z, Zhu Y, Yang L, Hu H, Sun Q, Liu M and Cao S (2024) <italic>Front. Immunol.</italic>&#xa0;15:1473145. doi:&#xa0;<object-id>10.3389/fimmu.2024.1473145</object-id>
</related-article>
<kwd-group>
<kwd>tumor immunotherapy</kwd>
<kwd>tumor vaccine</kwd>
<kwd>neoantigen</kwd>
<kwd>MHC molecular affinity</kwd>
<kwd>colorectal cancer</kwd>
</kwd-group>
<counts>
<fig-count count="1"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="3"/>
<word-count count="802"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>In the published article, there was two error in affiliation(s) 2.</p>
<p>1. Instead of &#x201c;<sup>3</sup>Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Hangzhou, China&#x201d;, it should be &#x201c;<sup>3</sup>Department of Psychiatry and Psychology, 155 Hospital of Kaifeng City, Kaifeng, China&#x201d;.</p>
<p>2. Instead of &#x201c;<sup>4</sup>Department of Urology, Huaihe Hospital, Henan University, Kaifeng City, China&#x201d;, it should be &#x201c;<sup>4</sup>Department of Urology, Huaihe Hospital of Henan University, Kaifeng, China&#x201d;.</p>
<p>In the published article, there was an error in the legend for <xref ref-type="fig" rid="f5">
<bold>
<bold>Figure 5</bold>
</bold>
</xref> as published. &#x201c;The percentages of T, B and NK cells in the mixed cells were identified by flow cytometry in control group shows the experimental group after adding peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 14.63%, 7.81% and 1.40%, respectively&#x201d; The corrected legend appears below.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The percentages of T, B, and NK cells in the mixed cell population were analyzed by flow cytometry in the control group, which did not include the addition of peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1514836-g005.tif"/>
</fig>
<p>&#x201c;The percentages of T, B, and NK cells in the mixed cell population were analyzed by flow cytometry in the control group, which did not include the addition of peptides. The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.&#x201d;</p>
<p>In the published article, there was an error in the <bold>Funding</bold> statement. &#x201c;This work was supported by grants from major science and technology project of Zhejiang Province, China (Project number: 4125C4011724448), the Hangzhou Science and Technology Development Program Project (Project number: 202004A21), Hangzhou Medical and Health Technology Project (Project number: A20220868), Hangzhou Biomedicine and Health Industry Development Support Project (Project number: 2022WJC030), and Henan Province Medical Science and Technology Research Program Project (Project number: LHGI20230440).&#x201d; The correct Funding statement appears below.</p>
<p>&#x201c;This work was supported by grants from major science and technology project of Zhejiang Province, China (Project number: 2017C03053), the Hangzhou Science and Technology Development Program Project (Project number: 202004A21), Hangzhou Medical and Health Technology Project (Project number: A20220868), Hangzhou Biomedicine and Health Industry Development Support Project (Project number: 2022WJC030), and Henan Province Medical Science and Technology Research Program Project (Project number: LHGI20230440).&#x201d;</p>
<p>In the published article, there were three errors.</p>
<p>1. A correction has been made to <bold>Abstract</bold>, <italic>Results</italic>, 1. This sentence previously stated:</p>
<p>&#x201c;3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 14.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.&#x201d;</p>
<p>The corrected sentence appears below:</p>
<p>&#x201c;3. Neoantigen Peptides Promote CD4+, CD8+ T, and NK Cell Proliferation: After 14 days, flow cytometry showed higher percentages of CD4+ T (37.41% vs 7.8%), CD8+ T (16.67% vs 4.63%), and NK cells (33.09% vs 7.81%) in the experimental group, indicating that the neoantigen peptides induced proliferation of CD4+, CD8+ T cells, and NK cells.&#x201d;</p>
<p>2. A correction has been made to <italic>3.3 The cellular immune effect induced by neoantigen peptides</italic>, <italic>3.3.2 Investigating the percentages of T, B and NK cells in the final activated immune cells</italic>, 1. This sentence previously stated:</p>
<p>&#x201c;The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 14.63%, 7.81% and 1.40%, respectively.&#x201d;</p>
<p>The corrected sentence appears below:</p>
<p>&#x201c;The proportions of CD3+CD4+ double positive (CD4+ T cells), CD3+CD8+ double positive (CD8+ T cells), CD3-CD56 + (NK cells) and CD3-CD19 + (B cells) were 7.8%, 4.63%, 7.81% and 1.40%, respectively.&#x201d;</p>
<p>3. A correction has been made to <bold>3 Results</bold>, <italic>3.4 Neoantigen peptide ELISpot results</italic>, 4. This sentence previously stated:</p>
<p>&#x201c;Immunogenicity quantification enabled determination of the relationship between a neoantigen&#x2019;s immune effects and its HLA molecular affinity changes, as depicted in Chart 1.&#x201d;</p>
<p>The corrected sentence appears below:</p>
<p>&#x201c;Immunogenicity quantification enabled determination of the relationship between a neoantigen&#x2019;s immune effects and its HLA molecular affinity changes, as depicted in Supplementary Material.&#x201d;</p>
<p>The authors apologize for these errors and state that these do not change the scientific conclusions of the article in any way. The original article has been updated.</p>
</body>
<back>
<sec id="s1" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</back>
</article>